The Usefulness Of The Combined Growth Hormone (GH) - PubMed

Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard Save Email Send to

• Clipboard
• My Bibliography
• Collections
• Citation manager

Display options Display options Format Abstract PubMed PMID

Save citation to file

Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel

Email citation

Subject: 1 selected item: 12519836 - PubMed To: From: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel

Add to Collections

• Create a new collection
• Add to an existing collection

Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Please try again Add Cancel

Add to My Bibliography

• My Bibliography

Unable to load your delegates due to an error Please try again Add Cancel

Your saved search

Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons

• Yes
• No

Email: (change) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel

Create a file for external citation management software

Create file Cancel

Your RSS Feed

Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy

Full text links

Silverchair Information Systems Full text links

Actions

CiteCollectionsAdd to Collections

• Create a new collection
• Add to an existing collection

Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an errorPlease try again Add Cancel Display options Display options Format AbstractPubMedPMID

Share

• Permalink Copy

Page navigation

• Title & authors
• Abstract
• Similar articles
• Cited by
• Publication types
• MeSH terms
• Substances
• Related information
• LinkOut - more resources

Title & authors Abstract Similar articles Cited by Publication types MeSH terms Substances Related information LinkOut - more resources Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

The diagnostic usefulness of the insulin tolerance test (ITT) in patients with radiation-induced GH deficiency (GHD) is well established, whereas that of the combined GHRH plus arginine stimulation test (AST) is unproven. Both tests were undertaken in 49 adult survivors (aged 16-53.7 yr), who were previously irradiated for non-pituitary brain tumors or leukemia, and 33 age-, gender-, and BMI-matched controls. The aims of the study were to examine the impact of the time interval after irradiation on the pattern of GH responsiveness to the two provocative tests and to establish the role of the GHRH + AST in the diagnosis of radiation-induced GHD. The median (range) peak GH responses to either test were significantly lower (P < 0.0001) in the patients [GHRH + AST, 19.9 (range, 2.7-103.5) microg/liter; ITT, 5 (0.2-34.8) microg/liter] than in normals [GHRH + AST, 55 (5.7-173.5) microg/liter; ITT, 23.8 (4.2-80) microg/liter]. In patients and normal controls, the median peak GH response to the GHRH + AST was significantly greater (P < 0.0001) than the response to the ITT. However, the ratio of the peak GH response to the GHRH + AST over that achieved with the ITT (discordancy ratio) was significantly higher (P = 0.007) in the patients (median, 3.45; range, 0.8-53.5) compared with normals (median, 2; range, 0.34-18.6), consistent with dominant hypothalamic damage and relatively preserved somatotroph responsiveness. The peak GH response to the ITT fell significantly within 5 yr of irradiation with little further change over the subsequent 10 yr. In contrast, the peak GH response to the GHRH + AST barely changed within 5 yr of irradiation but subsequently declined significantly over the next 10 yr. Thus, the evolution of change in GH responsiveness to the two different stimuli over time was markedly different, resulting in a significantly raised discordancy ratio of 6 within the first 5 postirradiation years, which then normalized over the next 10 yr. The peak GH responses to the GHRH + AST and the discordancy ratio were negatively correlated with the time interval after irradiation (r = -0.40, P = 0.0037; and r = -0.4, P = 0.0046, respectively). On a practical clinical level, the discordancy between the GH test results was important; 50% of those classified as severely GHD patients by the ITT were judged normal or only GH insufficient by the GHRH + AST. In conclusion, these findings suggest that hypothalamic dysfunction occurs early and somatotroph dysfunction occurs late, following radiation damage to the hypothalamic-pituitary axis. This time dependency of somatotroph dysfunction may reflect either secondary somatotroph atrophy due to hypothalamic GHRH deficiency or delayed direct radiation-induced damage to the pituitary gland. The high false negative diagnosis rate for severe GHD makes the GHRH + AST an unreliable test in clinical practice when GH status is explored in the early years after cranial irradiation with the intention to treat.

PubMed Disclaimer

Similar articles

• The impact of cranial irradiation on GH responsiveness to GHRH plus GH-releasing peptide-6. Popovic V, Pekic S, Golubicic I, Doknic M, Dieguez C, Casanueva FF. Popovic V, et al. J Clin Endocrinol Metab. 2002 May;87(5):2095-9. doi: 10.1210/jcem.87.5.8485. J Clin Endocrinol Metab. 2002. PMID: 11994347
• Growth hormone releasing hormone plus arginine stimulation testing in young adults treated in childhood with cranio-spinal radiation therapy. Ham JN, Ginsberg JP, Hendell CD, Moshang T Jr. Ham JN, et al. Clin Endocrinol (Oxf). 2005 May;62(5):628-32. doi: 10.1111/j.1365-2265.2005.02272.x. Clin Endocrinol (Oxf). 2005. PMID: 15853837
• Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test. Aimaretti G, Baffoni C, Bellone S, Di Vito L, Corneli G, Arvat E, Benso L, Camanni F, Ghigo E. Aimaretti G, et al. J Clin Endocrinol Metab. 2000 Oct;85(10):3693-9. doi: 10.1210/jcem.85.10.6858. J Clin Endocrinol Metab. 2000. PMID: 11061526 Clinical Trial.
• Diagnosis of adult GH deficiency. Ghigo E, Aimaretti G, Corneli G. Ghigo E, et al. Growth Horm IGF Res. 2008 Feb;18(1):1-16. doi: 10.1016/j.ghir.2007.07.004. Epub 2007 Sep 4. Growth Horm IGF Res. 2008. PMID: 17766155 Review.
• Update on the diagnosis of GH deficiency in adults. Abs R. Abs R. Eur J Endocrinol. 2003 Apr;148 Suppl 2:S3-8. doi: 10.1530/eje.0.148s003. Eur J Endocrinol. 2003. PMID: 12670294 Review.

See all similar articles

Cited by

• Could low prolactin levels after radiotherapy predict the onset of hypopituitarism? Mele C, Pigni S, Caputo M, Birtolo MF, Ciamparini C, Mazziotti G, Lania AGA, Marzullo P, Prodam F, Aimaretti G. Mele C, et al. Rev Endocr Metab Disord. 2024 Aug 22. doi: 10.1007/s11154-024-09900-1. Online ahead of print. Rev Endocr Metab Disord. 2024. PMID: 39172174 Review.
• Diagnosing and treating the elderly individual with hypopituitarism. Corsello A, Paragliola RM, Salvatori R. Corsello A, et al. Rev Endocr Metab Disord. 2024 Jun;25(3):575-597. doi: 10.1007/s11154-023-09870-w. Epub 2023 Dec 27. Rev Endocr Metab Disord. 2024. PMID: 38150092 Review.
• Pituitary dysfunction following mild traumatic brain injury in female athletes. Eggertsdóttir Claessen LÓ, Kristjánsdóttir H, Jónsdóttir MK, Lund SH, Unnsteinsdóttir Kristensen I, Sigurjónsdóttir HÁ. Eggertsdóttir Claessen LÓ, et al. Endocr Connect. 2024 Jan 16;13(2):e230363. doi: 10.1530/EC-23-0363. Print 2024 Feb 1. Endocr Connect. 2024. PMID: 38078923 Free PMC article.
• Expert Opinion on the Management of Growth Hormone Deficiency in Brain Tumor Survivors: Results From an Italian Survey. Di Iorgi N, Morana G, Cappa M, D'Incerti L, Garrè ML, Grossi A, Iughetti L, Matarazzo P, Parpagnoli M, Pozzobon G, Salerno M, Sardi I, Wasniewska MG, Zucchini S, Rossi A, Maghnie M. Di Iorgi N, et al. Front Endocrinol (Lausanne). 2022 Jul 14;13:920482. doi: 10.3389/fendo.2022.920482. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35909559 Free PMC article.
• Influence of biochemical diagnosis of growth hormone deficiency on replacement therapy response and retesting results at adult height. Rodari G, Profka E, Giacchetti F, Cavenaghi I, Arosio M, Giavoli C. Rodari G, et al. Sci Rep. 2021 Jul 15;11(1):14553. doi: 10.1038/s41598-021-93963-6. Sci Rep. 2021. PMID: 34267285 Free PMC article.

See all "Cited by" articles

Publication types

• Comparative Study Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Research Support, Non-U.S. Gov't Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

MeSH terms

• Adolescent Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Adult Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Arginine* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Deficiency Diseases / diagnosis Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Deficiency Diseases / etiology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Female Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Growth Hormone-Releasing Hormone* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Human Growth Hormone / deficiency* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Humans Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Insulin Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Insulin-Like Growth Factor I / analysis Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Male Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Middle Aged Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Prolactin / blood Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Radiotherapy / adverse effects* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Time Factors Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Substances

• Insulin Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Human Growth Hormone Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Insulin-Like Growth Factor I Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Prolactin Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Growth Hormone-Releasing Hormone Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Arginine Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Related information

• MedGen
• PubChem Compound
• PubChem Compound (MeSH Keyword)
• PubChem Substance

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information

Full text links [x] Silverchair Information Systems [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM Send To

• Clipboard
• Email
• Save
• My Bibliography
• Collections
• Citation Manager

[x]

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.